Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alphabet Inc. stock logo
GOOGL
Alphabet
$346.59
+1.7%		$349.62
$206.20
▼
$408.61
$4.24T1.2431.53 million shs25.26 million shs
Microsoft Corporation stock logo
MSFT
Microsoft
$513.53
+1.7%		$430.87
$349.20
▼
$553.72
$3.81T1.1136.66 million shs29.12 million shs
NVIDIA Corporation stock logo
NVDA
NVIDIA
$217.55
-4.6%		$208.09
$164.07
▼
$236.54
$5.26T2.23159.72 million shs194.28 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$3.34
-2.9%		$3.32
$2.77
▼
$7.18
$1.79B1.0318.14 million shs10.54 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alphabet Inc. stock logo
GOOGL
Alphabet
-0.39%-0.01%+2.08%-10.44%+64.18%
Microsoft Corporation stock logo
MSFT
Microsoft
+1.75%+4.97%+28.40%+12.18%-0.33%
NVIDIA Corporation stock logo
NVDA
NVIDIA
+8.74%+5.13%+15.72%+7.98%+25.54%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-1.43%+2.99%+12.79%-4.18%-29.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alphabet Inc. stock logo
GOOGL
Alphabet
$346.59
+1.7%		$349.62
$206.20
▼
$408.61
$4.24T1.2431.53 million shs25.26 million shs
Microsoft Corporation stock logo
MSFT
Microsoft
$513.53
+1.7%		$430.87
$349.20
▼
$553.72
$3.81T1.1136.66 million shs29.12 million shs
NVIDIA Corporation stock logo
NVDA
NVIDIA
$217.55
-4.6%		$208.09
$164.07
▼
$236.54
$5.26T2.23159.72 million shs194.28 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$3.34
-2.9%		$3.32
$2.77
▼
$7.18
$1.79B1.0318.14 million shs10.54 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alphabet Inc. stock logo
GOOGL
Alphabet
-0.39%-0.01%+2.08%-10.44%+64.18%
Microsoft Corporation stock logo
MSFT
Microsoft
+1.75%+4.97%+28.40%+12.18%-0.33%
NVIDIA Corporation stock logo
NVDA
NVIDIA
+8.74%+5.13%+15.72%+7.98%+25.54%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-1.43%+2.99%+12.79%-4.18%-29.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alphabet Inc. stock logo
GOOGL
Alphabet
3.04
Buy$420.1921.24% Upside
Microsoft Corporation stock logo
MSFT
Microsoft
2.89
Moderate Buy$560.279.10% Upside
NVIDIA Corporation stock logo
NVDA
NVIDIA
2.96
Moderate Buy$322.6148.29% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.20
Hold$8.06141.32% Upside

Current Analyst Ratings Breakdown

Latest GOOGL, MSFT, RXRX, and NVDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
8/27/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOutperform$465.00
8/27/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetStrong-Buy$352.00 ➝ $515.00
8/27/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$280.00 ➝ $300.00
8/27/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOverweight$288.00 ➝ $300.00
8/27/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$315.00 ➝ $400.00
8/27/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOutperform$265.00 ➝ $315.00
8/27/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$315.00
8/27/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$300.00 ➝ $315.00
8/27/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
Rosenblatt Securities logo
Rosenblatt Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$325.00 ➝ $390.00
8/27/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOutperform$315.00 ➝ $400.00
(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alphabet Inc. stock logo
GOOGL
Alphabet
$402.84B10.52$12.84 per share26.99$50.90 per share6.81
Microsoft Corporation stock logo
MSFT
Microsoft
$331.84B11.49$23.31 per share22.03$59.58 per share8.62
NVIDIA Corporation stock logo
NVDA
NVIDIA
$215.94B24.38$4.90 per share44.38$6.47 per share33.62
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$74.68M23.94N/AN/A$1.71 per share1.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alphabet Inc. stock logo
GOOGL
Alphabet
$132.17B$19.9117.4123.510.9654.77%51.32%35.42%10/28/2026 (Estimated)
Microsoft Corporation stock logo
MSFT
Microsoft
$133.75B$17.9628.5922.151.6040.31%31.98%18.70%10/28/2026 (Estimated)
NVIDIA Corporation stock logo
NVDA
NVIDIA
$120.07B$6.5327.5017.280.4163.66%107.00%80.43%N/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$644.76M-$1.04N/AN/AN/A-945.94%-50.41%-38.25%11/4/2026 (Estimated)

Latest GOOGL, MSFT, RXRX, and NVDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/26/2026Q2 2027
NVIDIA Corporation stock logo
NVDA
NVIDIA
$2.09$2.22+$0.13$2.46$92.27 billion$96.22 billion
8/5/2026Q2 2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.24-$0.25-$0.01-$0.25$10.97 million$7.67 million
7/29/2026Q4 2026
Microsoft Corporation stock logo
MSFT
Microsoft
$4.24$4.74+$0.50$4.81$87.62 billion$90.01 billion
7/22/2026Q2 2026
Alphabet Inc. stock logo
GOOGL
Alphabet
$2.89$9.11+$6.22$9.11$117.07 billion$119.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alphabet Inc. stock logo
GOOGL
Alphabet
$0.880.25%N/A4.42%1 Years
Microsoft Corporation stock logo
MSFT
Microsoft
$3.640.71%+10.21%20.27%23 Years
NVIDIA Corporation stock logo
NVDA
NVIDIA
$1.000.46%+14.87%15.31%1 Years
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A

Latest GOOGL, MSFT, RXRX, and NVDA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/26/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
quarterly$0.250.48%9/10/20269/10/202610/1/2026
7/22/2026
Alphabet Inc. stock logo
GOOGL
Alphabet
quarterly$0.220.28%9/4/20269/7/20269/14/2026
6/10/2026
Microsoft Corporation stock logo
MSFT
Microsoft
quarterly$0.910.76%8/20/20268/20/20269/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alphabet Inc. stock logo
GOOGL
Alphabet
0.16
2.72
2.64
Microsoft Corporation stock logo
MSFT
Microsoft
0.07
1.23
1.22
NVIDIA Corporation stock logo
NVDA
NVIDIA
0.04
3.44
2.85
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.01
5.03
5.03

Institutional Ownership

CompanyInstitutional Ownership
Alphabet Inc. stock logo
GOOGL
Alphabet
40.03%
Microsoft Corporation stock logo
MSFT
Microsoft
71.13%
NVIDIA Corporation stock logo
NVDA
NVIDIA
65.27%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%

Insider Ownership

CompanyInsider Ownership
Alphabet Inc. stock logo
GOOGL
Alphabet
11.61%
Microsoft Corporation stock logo
MSFT
Microsoft
0.03%
NVIDIA Corporation stock logo
NVDA
NVIDIA
3.94%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
6.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alphabet Inc. stock logo
GOOGL
Alphabet
190,82012.23 billion10.81 billionOptionable
Microsoft Corporation stock logo
MSFT
Microsoft
223,0007.43 billion7.42 billionOptionable
NVIDIA Corporation stock logo
NVDA
NVIDIA
42,00024.20 billion23.25 billionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400535.34 million499.74 millionOptionable

Recent News About These Companies

Recursion Pharmaceuticals, Inc. (RXRX)
August 26 at 8:14 PM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/RXRX/earnings-calls/
Stock Traders Purchase High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)
August 26 at 1:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-stock-traders-purchase-high-volume-of-recursion-pharmaceuticals-call-options-nasdaq-rxrx-2026-08-26/
Bank of America Corp DE Buys 384,486 Shares of Recursion Pharmaceuticals, Inc. $RXRX
August 26 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-buys-384486-shares-of-recursion-pharmaceuticals-inc-rxrx-2026-08-26/
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.3% - Here's What Happened
August 25 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-recursion-pharmaceuticals-nasdaq-rxrx-stock-price-up-63-heres-what-happened-2026-08-25/
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 7% - Here's What Happened
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-nasdaqrxrx-trading-down-7-heres-what-happened-2026-08-24/
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Rating of "Hold" by Analysts
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-inc-nasdaqrxrx-given-average-rating-of-hold-by-analysts-2026-08-24/
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 9.8% - Still a Buy?
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-nasdaqrxrx-shares-up-98-still-a-buy-2026-08-19/
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
August 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zacks-analyst-blog-highlights-recursion-074300158.html
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/contineum-disc-medicine-recursion-advance-150138340.html
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
August 17, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975676/4-ai-powered-drug-discovery-stocks-to-watch-as-ai-reshapes-pharma?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2975676
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-highlights-ai-platform-roche-progress-and-pipeline-updates-2026-08-17/
Recursion (RXRX) Q2 2026 Earnings Call Transcript
August 12, 2026  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/08/12/recursion-rxrx-q2-2026-earnings-call-transcript/
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934810-recursion-pharmaceuticals-inc-rxrx-presents-at-bank-of-america-smid-cap-virtual-conference
Stock Traders Purchase High Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX)
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/stock-traders-purchase-high-volume-of-put-options-on-recursion-pharmaceuticals-nasdaqrxrx-2026-08-11/
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
August 11, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/08/11/the-biggest-ipo-of-the-year-is-targeted-in-the-next-60-days-why-one-unexpected-industry-could-rally-before-then-its-not-tech/
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
August 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934323-recursion-pharmaceuticals-im-still-bearish-despite-recent-genentech-news
TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)
August 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RXRX/pressreleases/3714554/td-cowen-keeps-their-hold-rating-on-recursion-pharmaceuticals-rxrx/
Recursion Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933927-recursion-pharmaceuticals-inc-2026-q2-results-earnings-call-presentation
Recursion Pharmaceuticals (NASDAQ:RXRX) Cut to "Strong Sell" at Wall Street Zen
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-nasdaqrxrx-cut-to-strong-sell-at-wall-street-zen-2026-08-08/
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 30,000 Shares of Stock
August 7, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rxrx-insider-buying-and-selling-2026-08-07/
Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/blake-borgeson-sells-30000-shares-of-recursion-pharmaceuticals-nasdaqrxrx-stock-2026-08-06/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Microsoft logo displayed on a wall-mounted plaque in a modern office lobby with glass partitions.
Microsoft Just Flipped the AI Spending Narrative Overnight
By Chris Markoch | July 30, 2026
Microsoft logo on a glass office building at dusk, reflecting tech sector sentiment and MSFT stock focus.
No Hangover: Revisiting Microsoft One Week After Earnings
By Chris Markoch | August 7, 2026
Microsoft logo and sign displayed in the lobby of a corporate office building with a glass meeting room.
Microsoft's Maia 300 Chip Targets NVIDIA's AI Dominance
By Chris Markoch | August 16, 2026
Office lobby with the Anthropic logo mounted on a concrete wall, potted plants, and glass entrance doors.
The Pre-IPO Playbook: How to Cash in on Anthropic Before the Bell
By Jeffrey Neal Johnson | August 19, 2026
Microsoft logo in faceted glass sphere in data center.
Microsoft's Sell-Off May Be a Gift, Not a Warning
By Chris Markoch | August 21, 2026
Alphabet stock logo

Alphabet NASDAQ:GOOGL

$346.59 +5.94 (+1.74%)
As of 04:00 PM Eastern

Alphabet Inc. offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. It is also involved in the sale of apps and in-app purchases and digital content in the Google Play and YouTube; and devices, as well as in the provision of YouTube consumer subscription services. The Google Cloud segment offers infrastructure, cybersecurity, databases, analytics, AI, and other services; Google Workspace that include cloud-based communication and collaboration tools for enterprises, such as Gmail, Docs, Drive, Calendar, and Meet; and other services for enterprise customers. The Other Bets segment sells healthcare-related and internet services. The company was incorporated in 1998 and is headquartered in Mountain View, California.

Microsoft stock logo

Microsoft NASDAQ:MSFT

$513.53 +8.47 (+1.68%)
As of 04:00 PM Eastern

Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.

NVIDIA stock logo

NVIDIA NASDAQ:NVDA

$217.55 -10.43 (-4.57%)
As of 04:00 PM Eastern

NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$3.34 -0.10 (-2.91%)
As of 04:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas